Ian Karp | VP, Investor and Public Relations |
Michael Kauffman | Co-Founder, CEO & Director |
Michael Falvey | EVP, CFO & Treasurer |
Sharon Shacham | Co-Founder, President, Chief Scientific Officer & Co-Chairman of Scientific Advisory Board |
Christopher Primiano | EVP, Chief Business Officer, General Counsel & Secretary |
Rick Bienkowski | RBC Capital Markets |
Arlinda Lee | Canaccord Genuity |
Eric Joseph | JPMorgan Chase & Co. |
Maurice Raycroft | Jefferies |
David Rusch | Leerink Partners |
Konstantinos Aprilakis | JMP Securities |
Jenny Leeds | Bank of America Merrill Lynch |
Good morning. My name is Crystal, and I will be your conference operator today. At this time I would like to welcome everyone to Karyopharm Therapeutics' Second Quarter 2018 Financial Results Conference Call. [Operator Instructions]. Please be advised that this call is being recorded at the company's request.